{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-384380","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-09-08T11:33:18+00:00","discovered_at":"2026-09-08T11:35:00.311837+00:00","generated_at":"2026-09-08T11:35:06.810914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene Q3 2026 net loss $32.5M; cash $266.3M; BLA filing on track for 4Q 2026","bullets":["Net loss $32.5M ($0.47/share) vs $29.0M ($0.57/share) year ago; cash $266.3M.","Total opex $34.0M vs $29.9M; R&D down $2.5M, G&A up $6.6M.","Pivotal Cohort 1 data update, pre-BLA FDA meeting, and BLA initiation all planned for 4Q 2026.","Surfactant cohort safety run-in cleared; KOL webinar on Oct 15, 2026.","Michael Heffernan became Chairman in July 2026, succeeding Richard Glickman."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-384380","json":"https://secwatch.observer/filing/0001193125-26-384380.json","markdown":"https://secwatch.observer/filing/0001193125-26-384380.md","text":"https://secwatch.observer/filing/0001193125-26-384380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/0001193125-26-384380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:35:06.810914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}